ArticleWorld journal of urology2025
Decision regret after external beam radiotherapy and high dose-rate brachytherapy boost for prostate cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decision regret in patients with rectal cancer undergoing multimodal therapy.Clinical and translational radiation oncology · 2026Article
- Regret concerning treatment decisions in patients with primary or secondary brain tumors - a cross-sectional exploratory bicentric analysis.Journal of neuro-oncology · 2026Article
- Decision regret after reirradiation of the primary site in patients with prostate cancer.Clinical and translational radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with localized prostate cancer have various treatment options. Decision regret from a patient's view is an unpleasant feeling concerning a decision in health care. We aimed to explore regret and its determinants after external beam radiotherapy (EBRT) with a high dose-rate brachytherapy (HDR-BT) boost as traditional method of treatment intensification.
methodsWe conducted a secondary analysis of a cross-sectional study. Patients were enrolled at least two years after EBRT + HDR-BT. Decision regret was measured using the Decision Regret Scale (0-100). Covariables included patient characteristics, dose to organs at risk and patient-reported outcomes (PRO) including EPIC- 26, EORTC QLQ-C30, and PSCC. We used Pearson's correlation and one-way ANOVA analyses.
resultsAmong 108 patients, the median age was 73 and the median interval since treatment was 4 years. The mean score of decision regret was 11 (SD: 14). No (0), mild (1-25), or strong (> 25) decision regret was present in 49% (53/108), 39% (42/108), and 12% (13/108) of the patients, respectively. PRO were associated with stronger decision regret including worse urinary incontinence (r = - 0.198; p = 0.046), worse urinary irritative/obstructive symptoms (r = - 0.203; p = 0.045), worse bowel function (r = - 0.312; p = 0.001), worse hormonal function (r = - 0.289; p = 0.003), lower levels of shared-decision making (r = - 0.292; p = 0.002), and lower patient satisfaction (r = - 0.326; p < 0.001).
conclusionLong-term decision regret is mild among patients with prostate cancer treated with EBRT + HDR-BT. PRO were associated with decision regret which should be respected in clinical practice.
trial registrationThe study protocol was registered prior to patient accrual on the Open Science Framework (doi.org/10.17605/OSF.IO/A6DC3).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.